Armata pharmaceuticals, inc. (APHB)
Balance Sheet / Yearly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13
Assets
Current assets
Cash and cash equivalents

24,209

6,033

8,690

13,192

5,535

9,663

4,499

5,798

8,206

5,132

7,725

8,962

2,202

5,711

3,967

7,144

6,173

9,370

11,737

14,351

16,625

6,581

9,786

12,550

16,435

20,355

Award receivable

1,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts receivable, net

-

-

-

-

-

-

-

-

-

-

-

-

15

-

24

18

14

125

40

-

0

100

27

136

12

8

Prepaid expenses and other current assets

567

622

652

1,010

407

697

615

322

537

253

264

282

343

602

570

576

566

521

785

512

413

339

448

526

345

297

Held-for-sale assets, net

-

-

592

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total current assets

25,776

6,655

9,934

14,202

5,942

10,360

5,114

6,120

8,743

5,385

7,989

9,244

2,560

6,313

4,561

7,738

6,753

10,016

12,562

14,863

17,038

7,020

10,261

13,212

16,792

20,660

Restricted cash

600

700

700

700

-

800

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Property and equipment, net

2,005

2,187

2,530

3,432

420

3,249

591

678

727

816

847

909

982

1,072

1,152

1,210

1,170

1,131

1,162

1,147

1,197

1,220

1,283

1,119

356

145

Acquired patents, net

-

-

-

-

238

-

253

261

268

276

284

292

299

307

315

323

330

338

346

354

-

369

-

-

-

-

Operating lease right-of-use asset

1,839

2,028

2,258

2,700

286

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

In-process research and development

10,256

10,256

10,256

10,256

2,731

-

4,661

4,661

4,661

4,661

4,661

4,661

10,461

10,461

12,446

12,446

12,446

12,446

12,446

12,446

12,446

12,446

12,446

12,446

-

-

In process research and development

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

12,446

12,446

Acquired patents, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

361

-

377

385

392

400

Goodwill acquired

3,490

3,490

3,490

3,490

-

-

-

-

-

-

-

-

-

-

7,562

7,562

7,562

7,562

7,562

7,562

7,562

7,562

7,562

7,562

7,562

7,562

Other assets

136

135

136

136

-

136

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total intangible assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

20,385

20,393

20,400

20,408

Total assets

44,102

25,451

29,304

34,916

9,617

14,545

10,619

11,720

14,399

11,138

13,781

15,106

14,302

18,153

26,036

29,279

28,261

31,493

34,078

36,372

38,604

28,617

31,929

34,724

37,548

41,213

Liabilities and stockholders' equity
Current liabilities
Accrued expenses

-

-

-

-

-

-

1,751

1,367

965

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable and accrued liabilities

1,447

1,278

1,261

1,768

1,757

536

-

-

-

1,968

949

1,856

1,109

2,735

2,173

2,239

2,003

1,044

1,153

1,365

1,547

1,167

1,840

1,366

886

2,147

Accounts payable

-

-

-

-

-

415

714

682

810

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued compensation

1,209

1,323

1,568

1,833

-

191

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred award liability

859

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred asset acquisition consideration

1,476

970

885

769

-

970

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Current portion of operating lease liabilities

1,366

1,308

1,251

1,264

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred rent

-

-

-

-

-

335

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

-

-

20

58

86

-

18

43

142

245

247

350

142

244

246

349

-

-

Accrued compensation

-

-

-

-

1,834

-

-

-

-

-

1,145

1,072

884

895

10

72

138

728

491

321

433

457

449

-

-

-

Dividends payable

-

-

-

-

-

-

-

-

-

-

38

38

38

-

953

970

368

368

368

131

-

-

-

-

-

-

Insurance premium liability

-

-

-

-

-

-

-

-

-

-

20

81

161

-

-

-

-

-

-

-

-

-

-

-

-

-

Notes payable (Note 8)

-

-

-

-

-

-

-

-

-

-

305

606

598

803

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

140

244

Total current liabilities

6,357

4,879

4,965

5,634

3,591

2,032

2,465

2,049

1,775

1,968

2,477

3,711

2,876

3,538

3,154

3,324

2,651

2,385

2,259

2,167

2,122

1,868

2,535

1,715

1,026

2,391

Deferred rent, net of current portion

-

-

-

-

-

810

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating lease liabilities, net of current portion

1,186

1,555

1,900

2,413

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred asset acquisition consideration, net of current portion

-

1,347

1,230

1,162

-

2,892

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Derivative liabilities

-

-

-

-

-

-

-

-

-

292

-

-

-

2,443

-

-

-

1,499

-

-

-

-

-

-

-

-

Asset acquisition derivative liability

-

-

-

-

33

1,117

154

185

187

-

400

387

2,329

-

1,649

1,466

-

-

-

-

-

-

-

-

-

-

Deferred tax liability

3,077

3,077

3,077

3,077

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Series B preferred stock derivative liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

91

-

2,127

10,032

19,425

12,320

-

-

-

-

Warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2

-

10

3,984

14,727

5,826

-

-

-

-

Accrued severance

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

98

210

-

-

-

Deferred tax liability

-

-

-

-

819

-

1,147

1,147

1,147

1,147

1,147

1,147

2,449

2,449

3,005

3,005

3,005

3,005

3,078

3,078

3,078

3,078

3,078

3,078

-

-

Other long-term liabilities

-

-

-

-

213

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Derivative preferred shares conversion liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

14,043

33,402

46,325

40,791

Derivative warrants liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

6,035

13,115

20,110

16,871

Deferred tax liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3,078

3,078

Accrued severance

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

210

-

-

-

Total long term liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

23,366

49,595

69,513

60,740

Total liabilities

10,620

10,858

11,172

12,286

4,656

6,851

3,766

3,381

3,109

3,407

4,024

5,245

7,654

8,430

7,808

7,795

5,749

6,889

7,474

19,261

39,352

23,190

25,901

51,310

70,539

63,131

$0.01 par value, 9,357,935 shares authorized at December 31, 2016 and 2015, respectively, no shares and 7,527,853 shares issued and outstanding at December 31, 2016 and 2015, respectively (liquidation preference of $0 and $13,383,000 at December 31, 2016 and 2015, respectively)

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

11,890

-

-

-

1,990

1,660

-

-

-

$0.01 par value; no shares authorized at September 30, 2017 and December 31, 2016; no shares issued and outstanding at September 30, 2017 and December 31, 2016

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

13,615

-

10,941

4,023

2,328

-

-

1,337

1,021

707

Stockholders' equity
Common stock, $0.01 par value; 217,000,000 shares authorized; 18,644,693 and 9,922,758 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively

186

99

99

99

328

51

165

165

165

95

93

85

165

16

111

111

59

59

59

57

2,779

40

1,872

1,872

1,825

1,825

Additional paid-in capital

195,895

172,015

170,968

168,509

414,566

145,685

408,684

408,564

408,465

401,842

401,518

400,851

391,097

391,067

389,977

390,858

374,472

375,177

375,895

378,761

370,644

365,403

362,001

360,917

358,748

358,828

Paid-in-capital - contingent shares

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,837

1,837

1,837

1,837

Accumulated deficit

-162,599

-157,521

-152,935

-145,978

-409,933

-138,042

-401,996

-400,390

-397,340

-394,206

-391,854

-391,075

-384,614

-381,360

-371,860

-369,485

-365,634

-362,522

-360,291

-365,730

-376,499

-362,006

-361,342

-382,549

-396,422

-385,115

Total stockholders' equity

33,482

14,593

18,132

22,630

4,961

7,694

6,853

8,339

11,290

7,731

9,757

9,861

6,648

9,723

18,228

21,484

8,897

12,714

15,663

13,088

-3,076

3,437

4,368

-17,923

-34,012

-22,625

Total liabilities and stockholders' equity

44,102

25,451

29,304

34,916

9,617

14,545

10,619

11,720

14,399

11,138

13,781

15,106

14,302

18,153

26,036

29,279

28,261

31,493

34,078

36,372

38,604

28,617

31,929

34,724

37,548

41,213